



HAL
open science

Study of the pharmacokinetic variability of azacytidine

Loïc Osanno, Laure Farnault, Julien Colle, Geoffroy Venton, Raphaëlle Fanciullino

► **To cite this version:**

Loïc Osanno, Laure Farnault, Julien Colle, Geoffroy Venton, Raphaëlle Fanciullino. Study of the pharmacokinetic variability of azacytidine. Séminaire annuel du Canceropôle PACA, Jul 2023, Fréjus St Raphael, France. hal-04355717

HAL Id: hal-04355717

<https://hal.science/hal-04355717>

Submitted on 20 Dec 2023




HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Loïc Osanno, Laure Farnault, Julien Colle, Geoffroy Venton, Raphaëlle Fanciullino
SMARTc, COMPO, CRCM INRIA Sophia Antipolis & Inserm U1068, Marseille

Introduction & Objectives




- Azacytidine (Vidaza®) is a nucleosid analog subcutaneously administered at a protocol dose of 75mg/m² 7d/28d.
- Metabolized by a highly polymorphic enzyme, cytidine deaminase (CDA).
- Investigate the CDA status and pharmacokinetics of Azacytidine.



Material & Methods



Results



Conclusion & perspectives

- ❖ The results show significant pharmacokinetic variability of Azacytidine for the same dose protocol.
- ❖ We do not observe overexposure in PM patients.
- ❖ It would be interesting to consider CDA activity relative to pathology.
- ❖ A goal could be to correlate pharmacokinetics with response

